Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 1/2 1

Status

Completed 369Terminated 89Recruiting 30Withdrawn 25Active not recruiting 15Unknown 10Not yet recruiting 5Suspended 1

Sponsor Class

OTHER 5

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 68Gemcitabine 64Cyclophosphamide 64toripalimab 62Paclitaxel 57pembrolizumab 55sintilimab 53Specimen Handling 53Surgical Procedures, Operative 52anlotinib 49Fluorouracil 49Magnetic Resonance Spectroscopy 48Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 38camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Filgrastim × Clear all
NCT07604233 2026-06-01

Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Myeloid

NCT06594939 2026-05-01

Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Medical College of Wisconsin

Phase 2 Not yet recruiting
31 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT07367178 2026-01-28

SATROPIN

MedSIR

Phase 2 Not yet recruiting
30 enrolled
Breast

Breast Neoplasms

NCT06763666 2025-01-08

CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

Nanfang Hospital, Southern Medical University

Phase 4 Not yet recruiting
172 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06504901 2024-07-17

Evaluation of Efficacy and Safety of PD-1 Monoclonal Antibody in Combination With rhG-CSF, IL-2, and CapeOX in Initially Resectable Synchronous Colorectal Liver Metastases

The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting
30 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡